GlassScriptPhysician profile
Peter A Reisz
NPI 1083091227
$3,134.08
in general payments reported to CMS, 2019-2025
14 companies · $1,704 in 2025
The $1,704 reported for 2025 was more than what 76% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $94.71 · 2022: $176 · 2023: $257 · 2024: $902 · 2025: $1,704.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,992 · Food and Beverage: $871.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,992.20 |
| Food and Beverage | $870.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $2,059.25 | 2024-2025 | |
| Urogen Pharma, INC. | $345.35 | 2023-2025 | Jelmyto |
| Olympus America INC. | $206.17 | 2025 | Itind System |
| Janssen Biotech, INC. | $118.21 | 2022-2023 | Erleada |
| Pfizer INC. | $94.74 | 2022-2023 | |
| Boston Scientific Corporation | $94.71 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $61.54 | 2022-2023 | Lynparza |
| Sumitomo Pharma America, INC. | $37.87 | 2023 | Gemtesa |
| Dendreon Pharmaceuticals LLC | $36.22 | 2023 | Provenge |
| Myriad Genetic Laboratories, INC. | $18.91 | 2024 | Prolaris |
| Medtronic, INC. | $17.91 | 2022 | |
| Coloplast Corp | $16.68 | 2022 | |
| Antares Pharma, INC. | $14.25 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.27 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Reisz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.